Leede Financial Has Positive Outlook of ONCY FY2025 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at Leede Financial lifted their FY2025 EPS estimates for Oncolytics Biotech in a research report issued to clients and investors on Monday, March 10th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of ($0.28) for the year, up from their prior forecast of ($0.29). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.28) per share. Leede Financial also issued estimates for Oncolytics Biotech's FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.26) EPS and FY2029 earnings at ($0.09) EPS.

A number of other research firms also recently weighed in on ONCY. Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th. Maxim Group decreased their price objective on Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating on the stock in a report on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Monday. Finally, Royal Bank of Canada decreased their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating on the stock in a research note on Monday. Three investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oncolytics Biotech has a consensus rating of "Buy" and a consensus price target of $4.00.

Oncolytics Biotech Trading Up 0.3 %

Shares of Oncolytics Biotech stock traded up $0.00 on Thursday, hitting $0.63. 118,147 shares of the company traded hands, compared to its average volume of 1,288,895. Oncolytics Biotech has a 12-month low of $0.58 and a 12-month high of $1.53. The firm's 50-day simple moving average is $0.76 and its 200 day simple moving average is $0.92. The company has a market cap of $53.44 million, a P/E ratio of -2.31 and a beta of 1.18.

Remove Ads

Hedge Funds Weigh In On Oncolytics Biotech

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock valued at $61,000 after purchasing an additional 24,997 shares during the period. International Assets Investment Management LLC lifted its holdings in Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after buying an additional 26,069 shares during the period. Vantage Point Financial LLC bought a new stake in shares of Oncolytics Biotech in the 4th quarter worth approximately $27,000. National Bank of Canada FI increased its stake in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock valued at $60,000 after buying an additional 42,955 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Oncolytics Biotech during the fourth quarter valued at approximately $90,000. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.